Clinical trial · Interventional
Comparison of F-18 FDG and C-11 Acetate PET in Multiple Myeloma
Comparison of F-18 FDG PET CT and PET MRI With C-11 Acetate PET CT and PET MRI in the Diagnosis of Active Multiple Myeloma Disease: a Pilot Study
NCT03262389CI-TRIAL-00050666completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Investigators are doing this study to determine which of four imaging techniques: Fludeoxyglucose Positron Emission Tomography (18 FDG PET) computerized tomography (CT), 18 FDG PET Magnetic resonance imaging (MRI), C-11 acetate PET CT, and C-11 acetate PET MRI) is the best test for finding sites of active myeloma disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Fludeoxyglucose PET CT | Drug | — | UNRESOLVED |
| Fludeoxyglucose PET MRI | Drug | — | UNRESOLVED |
| Sodium Acetate C11 PET CT | Drug | — | UNRESOLVED |
| Sodium Acetate C11 PET MRI | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Multiple Myeloma Patients
- description
- Participants will receive 4 different techniques of diagnosis: Fludeoxyglucose (F-18 FDG) PET/MRI, Sodium Acetate (C-11 acetate) PET/CT, C-11 PET/MRI, and F-18 FDG PET/CT. Each participant will receive both PET drugs by both diagnostic techniques and is therefore included in the analysis population for the four reporting groups.
- interventionNames
- Drug: Fludeoxyglucose PET CT
- Drug: Sodium Acetate C11 PET CT
- Drug: Fludeoxyglucose PET MRI
- Drug: Sodium Acetate C11 PET MRI
Primary outcomes (1)
- measure
- Mean Multiple Myeloma Lesions Detected
- timeFrame
- Day 1, Day 2
- description
- The number of lesions detected in the scans will be averaged for each technique. Two techniques (scans) will be tested on Day 1 and two techniques (scans) will be tested on Day 2.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients being staged for multiple myeloma as follows: new diagnosis, high risk smoldering multiple myeloma, relapsed as defined by investigator * Patients who have undergone standard of care workup * 300 pounds or less * Can provide informed consent * Scheduled for a clinically indicated F-18 FDG PET scan * English speaking Exclusion Criteria: * Pregnant, breast feeding * Concurrent active non-multiple myeloma malignancy * Contraindication to PET MRI * Previous Type I or Type II Diabetes mellitus or a fasting blood glucose \>150 mg/dl
References
Publications (0)
Data not yet available
No reference posted for this study.